Hyubika Tablet 5/40 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
(Ltd.) Hubist Pharmaceutical
MFDS item code 201907022 · Approved 2019.10.02
This product's status changed to Expired on 2024.10.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not adequately controlled with monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled with either amlodipine or olmesartan medoxomil monotherapy. This helps manage blood pressure more effectively and reduce the risk of cardiovascular diseases. This treatment contributes to improving blood pressure control and preventing complications. Therefore, it is used to maintain the patient's safe blood pressure.
This medicine should be administered as 1 tablet once daily with water, regardless of meals. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil); however, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance 20-60mL/min) is 20 mg once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended that treatment be initiated at a low dose while the patient's condition is carefully monitored. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine, under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Patients should not take this medicine if they have an allergy to any of its components or similar classes of drugs, if they are pregnant or breastfeeding, or if they have severe liver diseases or specific heart conditions. It should be used with caution in patients who are depleted of fluids or salt, have severe hypotension, or have heart or lung problems, as this medication can significantly lower blood pressure which requires close monitoring. While taking this medication, side effects such as dizziness, headache, hypotension, indigestion, and rash may occur, so patients should consult a doctor if symptoms are severe. Especially when this medication is taken in conjunction with other drugs for hypertension treatment, the potential for interactions exists, so appropriate management should be discussed with a specialist. During pregnancy, this medication should be replaced with another safer treatment wherever possible due to the risks it poses to the fetus, and if this medication is taken during pregnancy, the fetus's condition should be monitored regularly. In breastfeeding, this medication can be transferred through breast milk and may cause side effects in the infant, so it is recommended to either stop breastfeeding or discontinue this medication. Patients under 18 years of age should not use this medication as its safety and efficacy have not been sufficiently established. Elderly patients may have impaired kidney or liver function, so they should start with a lower dose and take it with caution. If this medication is overdosed, severe hypotension or cardiac arrhythmias may occur, necessitating immediate emergency treatment. The medication should be kept out of reach of children, stored away from direct sunlight and moisture, and transferring it to other containers should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is also best kept at room temperature between 1 to 30 degrees Celsius. Avoid storing in excessively hot or cold places to maintain the effectiveness of the medication.
Pale yellow round film-coated tablet
30 tablets/PTP [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
(Ltd.) Hubist Pharmaceutical
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.